Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 319-329

  Novitzky, N ^a,b   Thomas, V ^a   Abrahams, L ^a   Du Toit, C ^a   McDonald, A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acute myelogenous leukemia; Anthracycline antibiotics; Resistant disease; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; BUSULFAN; CEPHALOSPORIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; OFLOXACIN; PREDNISONE; SARCOLYSIN; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER RESISTANCE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN DETERMINATION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3342925902     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20120     Document Type: Article

References (46)

1. Omura GA, Vogler WR, Lfante J et al. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance chemotherapy or BCG immunotherapy. Cancer 1982;49:1530-1536.
2. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987;69:1441-1449.
3. Rai KR, Holand JF, Glidewell OJ. et al. Treatment of acute myelogenous leukemia: a study by Cancer and Leukemia Group B. Blood 1981;1203-1212.
4. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-2526.
5. Weick J, Kopecky K, Appelbaum F, et al. A randomised investigation of high dose vs. standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myelogenous leukemia: a SWOG study. Blood 1996;88:2841-2848.
6. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990;75:27-32.
7. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]. Blood 1996;87(5):1710-1717.
8. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93(12):4116- 4124.
9. Stein AS, O'Donnell MR, Slovak ML, et al. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000;14(7):1191-1196.
10. Weil M, Glidewell OJ, Jacquillat C, et al. Daunorubicin in the therapy of granulocytic leukemia. Cancer Res 1973;33:921.
11. Yates J, Glidewell OJ, Wiernick P, et al. Cytosine arabinoside with daunorubicin or adriamycin therapy in patients with acute myelocytic leukemia: a CALGB study. Blood 1982;60:454.
12. Scott CS, Den GJ, Ottolander D, et al. Recommended procedures for the classification of acute leukaemias. Leuk Lymph 1993;11:37-49.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451-458.
14. Keating S, Suciu S, De Witte T, et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996;17:993-1001.
15. Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979;148(6):871-875.
16. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13:597-611.
17. Novitzky N, Thomas V, Hale G, Waldmann H. Ex vivo T cell depletion of bone marrow grafts with CAMPATH 1 is an effective measure to prevent graft versus host disease without abrogating the antileukaemic effect of transplantation. Transplantation 1999;67:620-626.
18. + cell determination by flow cytometry. J Hematotherapy 1996;5:213-226.
19. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26(1):69-76.
20. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292(17):895-902.
21. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
22. Mandelli F, Lipis E, Grignani F, et al. Daunomycin, cytosine arabinoside and thioguanine (DAT) vs vincristine, cytosine arabinoside and thioguanine (VAT) in the induction treatment of acute nonlymphocytic leukemia: a randomised collaborative study. Med Pediatr Oncol 1978;4:231-240.
23. Wiernick PH, Glidewell OJ, Hoagland HC, et al. A comparative trial of daunorubicin, cytosine arabinoside and thioguanine and a combination of the three agents for the treatment of acute myelogenous leukemia. Med Pediatr Oncol 1979;6:261-277.
24. Mayer RJ. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 1987;14(4):384-396.
25. Plunkett W, Iacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-β-D-arabinofuranosylcytosine. Scand J Hematol 1986;44:51-59.
26. Hines JD, Oken MM, Mazza J, et al. High dose cytarabine and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia. J Clin Oncol 1984;2(Suppl 1):545-549.
27. Champlin R, Gajewski J, Nimer S, et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation therapy. J Clin Oncol 1990;8:1199-1206.
28. Appelbaum FR, Dahlberg S, Thomas ED. Bone marrow transplantation or chemotherapy after remission induction for adults with acute non-lymphoblastic leukemia. A prospective comparison. Ann Intern Med 1984;101:581.
29. Baudard M, Bauchaud-Nicod A, Delmer A, Rio B, et al. Has the prognosis of adult patients with acute myeloid leukaemia improved over years? A single institution experience of 748 consecutive patients over 16-year period. Leukaemia 1999;13:1481-1490.
30. Du Toit ED, Mc Greggor KJ, Taljaard DG, et al. HLA-A, B, C, DR and DQ polymorphisms in three South African population groups: South African Negroes, Cape Coloureds and South African Caucasoid. Tissue Antigens 1988;31:109-125.
31. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-1674.
32. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-319.
33. Mitus AJ, Miller KB, Schenkein DP, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560-569.
34. Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical transplantation for acute myelogenous leukemia in first complete remission. Blood 2000;96:1254-1258.
35. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986;314:729-735.
36. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988;71:293-298.
37. Maraninchi D, Gluckman E, Biaise D, et al. Impact of T cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias. Lancet 1987;ii:75-78.
38. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988;69(2):239-245.
39. De Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001;98(8): 2326-2331.
40. Nademanee AP, O'Donnell MR, Schmidt GM, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993;82:2920-2928.
41. Frassoni F, Labopin M, Gluckman E, et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994;8:924-928.
42. Jourdan E, Maraninchi D, Reiffers J, et al. Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle). Leukemia 1995;9:1068-1071.
43. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332(4):217-223.
44. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304(25):1529-1533.
45. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [see comments]. N Engl J Med 1998;339:1649-1656.
46. Novitzky N, Thomas V, Stubbings H. Intensified myeloablative therapy and autologous stem cell transplantation for patients with acute myelogenous leukaemia: single centre experience. Cytotherapy 2003;5:139-146.